Skip to content

Study · Randomized controlled trial · n = 3,731 · 2017

5 results

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.

von Scholten BJ, Davies MJ, Persson F, Hansen TW, Madsbad S, Endahl L, Jepsen CH, Rossing P

Journal of diabetes and its complications11 Apr 2017Cited by 6 (Europe PMC)

PMID28462892 (opens in a new tab)DOI10.1016/j.jdiacomp.2017.04.003 (opens in a new tab)PepBankPUB-28462892
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people without type 2 diabetes in the SCALE Obesity and Prediabetes trial, liraglutide 3.0 mg produced greater weight loss at week 56 than placebo.

    In plain wordsIn adults without type 2 diabetes, liraglutide 3.0 mg led to more weight loss than placebo after 56 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss at week 56 (SCALE Obesity and Prediabetes)
    Study

    n = 3,731

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    In SCALE Obesity and Prediabetes, mean (±SD) weight loss (baseline to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo)
    1 context sentence
    Summary · context
    We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.
  2. 02HumanRandomized controlled trialOther

    In adults without type 2 diabetes, serum creatinine was similar at baseline and week 56, and similar across liraglutide and placebo groups.

    In plain wordsIn adults without type 2 diabetes, kidney blood markers stayed similar after 56 weeks of liraglutide, as with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerum creatinine at week 56 (SCALE Obesity and Prediabetes)
    Study

    n = 3,731

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar across treatment groups)
    1 context sentence
    Summary · context
    We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide 3.0 mg produced greater weight loss at week 56 than placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide 3.0 mg led to more weight loss than placebo after 56 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss at week 56 (SCALE Diabetes)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    In SCALE Diabetes, weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo)
    1 context sentence
    Summary · context
    We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.
  4. 04HumanRandomized controlled trialOther

    In adults with type 2 diabetes, serum creatinine was unchanged from baseline to week 56 with liraglutide and with placebo.

    In plain wordsIn adults with type 2 diabetes, kidney blood markers stayed about the same after 56 weeks of liraglutide, as with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerum creatinine at week 56 (SCALE Diabetes)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo).
    1 context sentence
    Summary · context
    We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.
  5. 05HumanRandomized controlled trialOther

    In both SCALE trials, changes in body weight on liraglutide 3.0 mg were not associated with changes in serum creatinine.

    In plain wordsIn both trials, weight changes on liraglutide 3.0 mg were not linked to changes in kidney blood markers.

    Peptide
    Liraglutide
    Outcome
    No significant changeAssociation between weight change and serum creatinine change
    Study

    n: not reported in source

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    No association between changes in weight and changes in serum creatinine was observed (P≥0.05, both trials, all tests).
    1 context sentence
    Summary · context
    We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk A/Sn = 3,7311 Jun 2011 to 2 Mar 2015

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 19 Jan 2018
CompletedPhase 3Results postedNCT01272232

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Novo Nordisk A/Sn = 8461 Jun 2011 to 25 Jan 2013

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 29 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.